FINGOLIMOD FOR MS
Fingolimod for relapsing or remitting multiple sclerosis: an assessment based on the manufacturer’s submission to NICE
BackgroundThe aim of this NICE STA was to appraise the clinical and cost-effectiveness of fingolimod within its licensed indication for the treatment of relapsing remitting multiple sclerosis (RRMS) in adults . CRD researchers together with researchers from the Centre for Health Economics (CHE) comprised the Evidence Review Group for this STA. The work involved a detailed assessment of the manufacturer’s submission to NICE on the clinical and cost-effectiveness of fingolimod.
The final scope issued by NICE states that fingolimod is considered for adults with RRMS but that guidance will only be issued in accordance with the marketing authorisation.Conducted by: Miqdad Asaria2, Gill Norman1, Sebastian Hinde2, Joanne O'Connor1, Stephen Palmer2, Kate Light1, Marta Soares2, Alison Eastwood1
1. Centre for Reviews and Dissemination 2. Centre for Health Economics, University of York
Further detailsProject page on NIHR HTA Programme website
Related guidanceCommissioned to inform NICE Technology Appraisal Guidance: Fingolimod for the treatment of relapsing-remitting multiple sclerosis. London: National Institute for Clinical Excellence; 2011
PublicationsCRD and CHE Technology Assessment Group. Fingolimod for the treatment of relapsing remitting multiple sclerosis. Centre for Reviews and Dissemination/Centre for Health Economics; 2011
Commissioned by the NIHR HTA Programme in support of NICE's Single Technology Appraisal process.
NICE’s single technology appraisal (STA) process is specifically designed for the appraisal of a single product, device or other technology, with a single indication. The STA process normally covers new technologies and is designed to provide recommendations in the form of NICE guidance soon after the technology is introduced into the UK market. The principal evidence in the STA process is submitted by the manufacturer or sponsor of the technology.